June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Outcomes of Bimatoprost sustained-release intracameral implant in patients with glaucoma
Author Affiliations & Notes
  • Michael K Wong
    Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, United States
  • Mallory Elva Bowers
    Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, United States
  • Jonas Ventimiglia
    University of Maryland at College Park, College Park, Maryland, United States
  • Rachel Niknam
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Marlene R Moster
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Michael J Pro
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Elizabeth Dale
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Natasha N Kolomeyer
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Daniel Lee
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Cindy X Zheng
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Michael Wong None; Mallory Bowers None; Jonas Ventimiglia None; Rachel Niknam Allergan, Code C (Consultant/Contractor); Marlene Moster AbbVie, Code C (Consultant/Contractor), AbbVie, Code F (Financial Support); Michael Pro None; Elizabeth Dale None; Natasha Kolomeyer AbbVie, Regeneron, Alimera, Genentech, Code C (Consultant/Contractor), AbbVie, Guardian Health Services Inc, Equinox, Nicox, Olleyes, Santen, Glaukos, Diopsys, Aerie, Code F (Financial Support); Daniel Lee Quidel Eye Health, Code C (Consultant/Contractor), Allergan, Equinox, Glaukos, Mati, Nicox, Olleyes, Santen, Code F (Financial Support); Cindy Zheng MicroSurgical Technology, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2837 – A0360. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael K Wong, Mallory Elva Bowers, Jonas Ventimiglia, Rachel Niknam, Marlene R Moster, Michael J Pro, Elizabeth Dale, Natasha N Kolomeyer, Daniel Lee, Cindy X Zheng; Outcomes of Bimatoprost sustained-release intracameral implant in patients with glaucoma. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2837 – A0360.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Bimatoprost sustained-release intracameral implant (Bimatoprost SR, Durysta, Allergan) was approved by the U.S. Food and Drug Administration for one-time use in patients with ocular hypertension or open angle glaucoma (OAG) in March 2020. The purpose of the present study is to determine real-world outcomes of Bimatoprost SR on intraocular pressure (IOP) and number of IOP lowering medications in patients with glaucoma. A secondary objective is to determine the efficacy of Bimatoprost SR in patients with a prior history of selective laser trabeculoplasty (SLT).

Methods : 122 eyes that received Bimatoprost SR by six glaucoma specialists at Wills Eye Hospital from March 2020 until September 2021 were examined using a retrospective chart review. A paired sample t-test for IOP and a binomial change test for number of medications was used. Multilevel models were then used to determine if statistical significance remained when controlling for demographic variables and prior history of SLT utilizing the lme4 package in R.

Results : Of the 122 eyes, there were 113 OAG, 4 chronic-angle closure, 3 ocular hypertension, and 2 others. 46 (54%) patients were female, and the median age was 78 years old. Mean follow-up time was 26.9 ± 18.9 weeks. 82 (67%) eyes were on a topical prostaglandin medication prior to intracameral Bimatoprost SR injection. 68 (83%) of these eyes stopped topical prostaglandin medication after injection. Mean post-treatment IOP of 16.6 ± 5.3 mmHg was significantly lower than mean pre-treatment IOP of 18.5 ± 5.8 mmHg (t=-3.50, p <0.01). The average number of medications following Bimatoprost SR was 1.3 ± 1.3, which was significantly lower than the average number of pre-treatment medications of 2.1 ± 1.4 (p<0.01). Analysis of multilevel models demonstrated that there was a statistically significant reduction in IOP and number of medications post-treatment even when demographic variables were controlled for (p<0.01 for both). A prior history of SLT (n=54) had no impact on treatment outcomes for IOP or number of medications, when controlling for demographics (p>0.1 for both).

Conclusions : Intracameral Bimatoprost SR reduced IOP and decreased the number of medications. Prior history of SLT did not impact Bimatoprost SR treatment outcomes.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×